Compare · ABT vs UPB
ABT vs UPB
Side-by-side comparison of Abbott Laboratories (ABT) and Upstream Bio Inc. (UPB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and UPB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 981.4x UPB ($184.6M).
- ABT has hit the wire 13 times in the past 4 weeks while UPB has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 10 for UPB).
- Company
- Abbott Laboratories
- Upstream Bio Inc.
- Price
- -
- -
- Market cap
- $181.14B
- $184.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 10
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest UPB
- General Counsel Ambrose Allison sold $2,663 worth of shares (485 units at $5.49), decreasing direct ownership by 3% to 15,563 units (SEC Form 4) to satisfy withholding tax
- CFO and COO Gray Michael sold $4,683 worth of shares (853 units at $5.49), decreasing direct ownership by 3% to 27,942 units (SEC Form 4) to satisfy withholding obligation
- Chief Medical Officer Deykin Aaron sold $4,914 worth of shares (895 units at $5.49), decreasing direct ownership by 3% to 32,302 units (SEC Form 4) (for withholding tax)
- Chief Business Officer Houghton Adam sold $3,843 worth of shares (700 units at $5.49), decreasing direct ownership by 3% to 22,901 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Sutherland Everett Rand sold $11,502 worth of shares (2,095 units at $5.49), decreasing direct ownership by 3% to 68,717 units (SEC Form 4) (withholding obligation)
- Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
- Upstream Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
- Amendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.
- SEC Form 10-Q filed by Upstream Bio Inc.